NASDAQ:PRTO

Proteon Therapeutics Stock Insider Trading

> Biotechnology

Buy PRTO

*Your capital is at risk

$27.88

-0.0562 (-0.201%)

At Close: Jun 03, 2026

Proteon Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 26.7M and sold 73.04M PRTO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	26.7M shares
● Sell	73.04M shares
71% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 12, 2019 Buy	Common Stock, $0.001 par value C-Conversion	Haines Timothy Former Director And 10% Owner	Director	126 645 Value: $126.0K
Nov 12, 2019 Sell	Series A Convertible Preferred Stock C-Conversion	Haines Timothy Former Director And 10% Owner	Director	126 Value: $125
Jan 18, 2019 Buy	Stock Option (Right to Buy) A-Award	Gottlieb Daniel Philip Vp Corporate Development	Officer	60 000 Value: $158.4K
Jan 18, 2019 Buy	Stock Option (Right to Buy) A-Award	Kowalsky Matthew Paul Vp, Legal And Secretary	Officer	60 000 Value: $158.4K
Jan 18, 2019 Buy	Stock Option (Right to Buy) A-Award	Hartman Bradley J Vp, People	Officer	70 000 Value: $184.8K
Dec 31, 2018 Buy	Common Stock A-Award	Kowalsky Matthew Paul Vp, Legal And Secretary	Officer	2 448 Value: $5K
Aug 01, 2018 Buy	Stock Option (Right to Buy) A-Award	Hartman Bradley J Vp, People	Officer	150 000 Value: $318.8K
Aug 01, 2018 Buy	Common Stock J-Other	Hartman Bradley J Officer	Officer	0 Value: $0
Jun 29, 2018 Buy	Common Stock A-Award	Kowalsky Matthew Paul Vp, Legal And Secretary	Officer	10 000 Value: $16.2K
Jun 08, 2018 Buy	Stock Option (Right to Buy) A-Award	Flynn James E *director By Deputization	Director	12 700 Value: $31.8K
Jun 08, 2018 Buy	Stock Option (Right to Buy) A-Award	Hastings Paul J Director	Director	12 700 Value: $31.8K
Jun 08, 2018 Buy	Stock Option (Right to Buy) A-Award	Haines Timothy	Director	12 700 Value: $31.8K
Jun 08, 2018 Buy	Stock Option (Right to Buy) A-Award	Canute Scott A Director	Director	12 700 Value: $31.8K
Jun 08, 2018 Buy	Stock Option (Right to Buy) A-Award	Birner Hubert	Director	12 700 Value: $31.8K
Jan 17, 2018 Buy	Stock Option (Right to Buy) A-Award	Kowalsky Matthew Paul Vp, Legal And Secretary	Officer	110 000 Value: $313.5K
Jan 17, 2018 Buy	Stock Option (Right to Buy) A-Award	Gottlieb Daniel Philip Vp Corporate Development	Officer	110 000 Value: $313.5K
Dec 29, 2017 Buy	Common Stock A-Award	Kowalsky Matthew Paul Vp, Legal And Secretary	Officer	3 934 Value: $5K
Nov 30, 2017 Buy	Common Stock P-Purchase	Flynn James E *director By Deputization	Director	110 557 Value: $193.5K
Nov 30, 2017 Sell	Common Stock S-Sale	Flynn James E *director By Deputization	Director	110 557 Value: $193.5K
Aug 02, 2017 Buy	Stock Option (Right to Buy) A-Award	Flynn James E *director By Deputization	Director	13 333 Value: $17.3K
Aug 02, 2017 Buy	Common Stock	Flynn James E *director By Deputization	Director	0 Value: $0
Aug 02, 2017 Buy	Common Stock	Flynn James E *director By Deputization	Director	0 Value: $0
Aug 02, 2017 Buy	Common Stock	Flynn James E *director By Deputization	Director	0 Value: $0
Aug 02, 2017 Buy	Common Stock	Flynn James E *director By Deputization	Director	0 Value: $0
Aug 02, 2017 Buy	Series A Convertible Preferred Stock	Flynn James E *director By Deputization	Director	16 082 018 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PROTEON THERAPEUTICS INC.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in two Phase III clinical trials in patients with chronic kidney disease undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis; has completed a Phase I/II clinical trials ...

Read Full Profile Here